1 the Circulating SARS-Cov-2 Spike Variant N439K Maintains
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.04.355842; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity Emma C. Thomson1,2*, Laura E. Rosen3*, James G. Shepherd1*, Roberto Spreafico3*, Ana da Silva Filipe1, Jason A. Wojcechowskyj3, Chris Davis1, Luca Piccoli4, David J. Pascall5, Josh Dillen3, Spyros Lytras1, Nadine Czudnochowski3, Rajiv Shah1, Marcel Meury3, Natasha Jesudason1, Anna De Marco4, Kathy Li1, Jessica Bassi4, Aine O’Toole6, Dora Pinto4, Rachel M. Colquhoun6, Katja Culap4, Ben Jackson6, Fabrizia Zatta4, Andrew Rambaut6, Stefano Jaconi4, Vattipally B. Sreenu1, Jay Nix7, Ruth F. Jarrett1, Martina Beltramello4, Kyriaki Nomikou1, Matteo Pizzuto4, Lily Tong1, Elisabetta Cameroni4, Natasha Johnson1, Arthur Wickenhagen1, Alessandro Ceschi8,9,10, Daniel Mair1, Paolo Ferrari11,12, Katherine Smollett1, Federica Sallusto13, Stephen Carmichael1, Christian Garzoni14, Jenna Nichols1, Massimo Galli15, Joseph Hughes1, Agostino Riva15, Antonia Ho1, Malcolm G. Semple16,17, Peter J.M. Openshaw18, J. Kenneth Baillie19,20, The ISARIC4C Investigators21, the COVID-19 Genomics UK (COG-UK) consortium22, Suzannah J. Rihn1, Samantha J. Lycett19, Herbert W. Virgin3,23, Amalio Telenti3, Davide Corti4, David L. Robertson1, and Gyorgy Snell3 1MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK 2Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK 3Vir Biotechnology, San Francisco, California 94158, USA 4Humabs BiomeD SA, a subsiDiary of Vir Biotechnology, 6500 Bellinzona, SwitzerlanD.
[Show full text]